Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase ...
Experts review warning nail features, from inflammatory conditions to tumours, offering practical guidance on diagnosis and ...
Mild hidradenitis suppurativa is often treated with cycles of steroids and antibiotics that have adverse effects. Can an anti ...
These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
Discover effective strategies to manage arthritis pain during winter, including diet, exercise, and warmth for improved ...
BENGALURU: As cold winter weather wrapped Karnataka after many years, the season also came with an unexpected test of ...
The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...
Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...
Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...
American Skin Association (ASA) is pleased to announce that Steven A. Rosenberg, MD, PhD, a pioneering figure in cancer immunotherapy, was appointed as the newest member of its distinguished Board of ...
RAAINBOW-2 is an international, double-blind, placebo-controlled Phase 3 study for the treatment of moderate to severe alopecia areata (AA) in at least 500 subjects. -- Cinainu is the first topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback